TY - JOUR
T1 - Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice
T2 - Imbalance of prefrontal serotonergic and dopaminergic functions
AU - Noda, Yukihiro
AU - Kamei, Hiroyuki
AU - Mamiya, Takayoshi
AU - Furukawa, Hiroshi
AU - Nabeshima, Toshitaka
N1 - Funding Information:
This work was supported, in part, by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (10044260) and by the Health Sciences Research Grants for Research on Pharmaceutical and Medical Safety from the Ministry of Health and Welfare of Japan.
PY - 2000/10
Y1 - 2000/10
N2 - Repeated treatment with phencyclidine (PCP) prolonged the immobility time in a forced swimming test, compared with saline treatment, this behavioral change being regarded as avolition which is one of the negative symptoms of schizophrenia. In the present study, we investigated an involvement of serotonergic (5-HTergic) and dopaminergic systems in PCP- induced enhancement of immobility in mice, since an alteration in 5-HTergic and dopaminergic systems has been hypothesized in schizophrenia. The enhancing effect of PCP on the immobility in a forced swimming test was attenuated by clozapine, risperidone and olanzapine, which have serotonin (5- HT) and dopamine receptor antagonistic properties. These attenuating effects were significantly antagonized by a 5-HT2 receptor agonist, (±)-2,5- dimethoxy-4-iodamphetamine (DOI) without affecting the immobility itself. (- )Sulpiride at a low dose and methylphenidate reversed the PCP-induced enhancement of immobility whereas pimozide, chlorpromazine and levomepromazine had no effect. There was no difference in the frequency of DOI-induced head twitches, which are mediated via 5-HT2 receptors, between PCP- and saline-treated mice following the forced swimming test, indicating no functional changes in post-synaptic 5-HT2 receptors. 5-HT utilization in the prefrontal cortex was increased, but dopamine utilization was decreased in mice showing PCP-induced enhancement of immobility. These results suggest that the enhanced effect of PCP on the immobility is mediated by imbalance of 5-HTergic and dopaminergic systems in the prefrontal cortex and could be used as a model of the negative symptoms of schizophrenia. (C) 2000 American College of Neuropsychopharmacology.
AB - Repeated treatment with phencyclidine (PCP) prolonged the immobility time in a forced swimming test, compared with saline treatment, this behavioral change being regarded as avolition which is one of the negative symptoms of schizophrenia. In the present study, we investigated an involvement of serotonergic (5-HTergic) and dopaminergic systems in PCP- induced enhancement of immobility in mice, since an alteration in 5-HTergic and dopaminergic systems has been hypothesized in schizophrenia. The enhancing effect of PCP on the immobility in a forced swimming test was attenuated by clozapine, risperidone and olanzapine, which have serotonin (5- HT) and dopamine receptor antagonistic properties. These attenuating effects were significantly antagonized by a 5-HT2 receptor agonist, (±)-2,5- dimethoxy-4-iodamphetamine (DOI) without affecting the immobility itself. (- )Sulpiride at a low dose and methylphenidate reversed the PCP-induced enhancement of immobility whereas pimozide, chlorpromazine and levomepromazine had no effect. There was no difference in the frequency of DOI-induced head twitches, which are mediated via 5-HT2 receptors, between PCP- and saline-treated mice following the forced swimming test, indicating no functional changes in post-synaptic 5-HT2 receptors. 5-HT utilization in the prefrontal cortex was increased, but dopamine utilization was decreased in mice showing PCP-induced enhancement of immobility. These results suggest that the enhanced effect of PCP on the immobility is mediated by imbalance of 5-HTergic and dopaminergic systems in the prefrontal cortex and could be used as a model of the negative symptoms of schizophrenia. (C) 2000 American College of Neuropsychopharmacology.
UR - http://www.scopus.com/inward/record.url?scp=0033828218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033828218&partnerID=8YFLogxK
U2 - 10.1016/S0893-133X(00)00138-X
DO - 10.1016/S0893-133X(00)00138-X
M3 - Article
C2 - 10989264
AN - SCOPUS:0033828218
SN - 0893-133X
VL - 23
SP - 375
EP - 387
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 4
ER -